A Canadian startup is out to rewrite one of the drug industry’s most painful cautionary tales, betting that an all-but-abandoned heart drug may actually work. But it’ll have to overcome significant evidence to the contrary and win over a deeply skeptical scientific establishment.

The company, DalCor Pharmaceuticals, is carrying the torch for the idea that improving good cholesterol, known as HDL, can prevent heart attacks and strokes for at-risk patients. It hopes its drug — part of a class of medicines called CETP inhibitors — can do just that by blocking what’s known as cholesterylester transfer protein.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy